IONIS PHARMACEUTICALS INC
Close on Oct 19, 2026
- Market cap
- $7.34B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 28, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 29, 2026 | Before market open | $268.00M | $-0.69 | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 29, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 25, 2026 | Before market open | $203.00M | $-1.41 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 29, 2025 | Before market open | $157.00M | $-0.80 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 30, 2025 | During market hours | $452.00M | $0.70 | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 30, 2025 | During market hours | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 19, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 21, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Jul 29, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| product sales | full year 2026 | $110.00M to $120.00M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Ionis Pharmaceuticals filed with the SEC
Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Ionis reports second quarter 2026 financial results and highlights progress on key programs
Results of operations · EX-99.1 to Form 8-K
Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
TRYNGOLZA ® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
Executive or director change · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Ionis reports first quarter 2026 financial results and highlights progress on key programs
Results of operations · EX-99.1 to Form 8-K
Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Ionis announces changes to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
Results of operations · EX-99.1 to Form 8-K
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data
Results of operations · EX-99.1 to Form 8-K
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Ionis reports third quarter 2025 financial results and highlights progress on key programs
Results of operations · EX-99.1 to Form 8-K
Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
DAWNZERA ™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Ionis reports second quarter 2025 financial results and highlights progress on key programs
Results of operations · EX-99.1 to Form 8-K
Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides
Other events · EX-99.1 to Form 8-K
Ionis reports first quarter 2025 financial results
Results of operations · EX-99.1 to Form 8-K
Ionis reports fourth quarter and full year 2024 financial results
Results of operations · EX-99.1 to Form 8-K
Ionis reports third quarter 2024 financial results
Results of operations · EX-99.1 to Form 8-K
Ionis reports second quarter 2024 financial results
Results of operations · EX-99.1 to Form 8-K
Ionis reports first quarter 2024 financial results
Results of operations · EX-99.1 to Form 8-K
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
Other events · EX-99.1 to Form 8-K
Ionis reports fourth quarter and full year 2023 financial results
Results of operations · EX-99.1 to Form 8-K
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary
Other events · EX-99.1 to Form 8-K
Ionis reports third quarter 2023 financial results
Results of operations · EX-99.1 to Form 8-K
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome
Other events · EX-99.1 to Form 8-K
Ionis reports second quarter 2023 financial results
Results of operations · EX-99.1 to Form 8-K
Eplontersen continued to show improvement in ATTRv-PN through 85 weeks
Other events · EX-99.1 to Form 8-K
Eplontersen: NEURO-TTRansform Week 85 Topline Results July 10, 2023 Nasdaq:
Other events · EX-99.2 to Form 8-K
Ionis prices private placement of convertible senior notes
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K